What to expect from PARP inhibitor therapy for pancreatic cancer

PARP inhibitors interfere with a DNA-repair route. Some pancreatic tumours carry changes in other repair pathways, which can make them more vulnerable to this approach. Your team may recommend inherited genetic testing and tumour testing to look for relevant findings before discussing treatment.

Treatment is taken by mouth according to a prescribed schedule. It may be considered after earlier therapy has controlled the cancer, or within a plan tailored to tumour findings and your health. It does not suit every pancreatic cancer, and a test result is only one part of the decision.

Use the same routine for doses and check how the medicine should be taken with food. Tell the team about all prescriptions, vitamins and herbal products before starting. If you vomit after a dose or forget one, call for specific instructions rather than taking an extra tablet.

Attend scheduled blood tests and appointments even when you feel well. Results may lead to a dose adjustment or short treatment break. Keep notes on appetite, bowel changes, abdominal discomfort, tiredness and any new symptom; pancreatic cancer care may also include support for digestion, nutrition and pain.

Call your cancer team promptly about fever, chills, infection symptoms, unusual bleeding or bruising, worsening breathlessness, severe weakness, repeated vomiting, inability to drink, or diarrhoea that does not settle. Low blood counts and dehydration can need prompt treatment.

Get urgent help for chest pain, severe breathing trouble, collapse, confusion or heavy bleeding. Tell any emergency clinician that you are receiving cancer medicine and show the medication packaging if possible.

Ask what tumour or inherited finding supports this option, whether the aim is control or maintenance, how often blood tests and scans are expected, which medicines or foods need checking, and what symptoms require immediate contact. Ask how pancreatic symptoms such as poor appetite, altered stools or pain will be supported alongside the PARP inhibitor.